#PLX hashtag - Bluesky

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Protalix (NYSE:PLX) reported fiscal 2025 results and business updates on March 18, 2026. Key developments include EC approval of a 2mg/kg every‑4‑weeks (E4W) Elfabrio dosing regimen for adults with Fabry disease, triggering a $25.0 million milestone from Chiesi and supporting an expected $50.0 million cash balance by April 2026.Management expects 2026 revenue of $78.0–$83.0 million (including the milestone), announced active enrollment in the Phase 2 PRX‑115 gout trial, and highlighted focus on rare renal programs and partnerships.

1 week ago

#PLX Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 Protalix BioTherapeutics (NYSE American: PLX) will release its fiscal year 2025 financial results and provide a business update on March 18, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT to discuss results and recent corporate and regulatory developments.Call-in numbers, webcast links, conference ID, and replay availability for two weeks on the company's investor events page are provided for investors and analysts.

2 weeks ago

#PLX Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

1 month ago

Original post on mastodon.social

Aviation weather for Semipalatinsk airport in Semey area (Kazakhstan) is “SPECI UASS 060508Z 17018G25MPS 1000 R26/1000 BLSN NSC M03/M05 Q1014 NOSIG RMK QFE743/0990” : See what it means on https://www.bigorre.org/aero/meteo/uass/en #semipalatinskairport #airport #semey #kazakhstan #uass #plx […]

0 0 0 0

Protalix BioTherapeutics Letter to Stockholders Protalix (NYSE: PLX) provided a stockholder update outlining 2026 priorities: commercial execution through partners, advancement of PRX-115 for uncontrolled gout, and a focused renal pipeline including PRX-119 and an RNA collaboration with Secarna.Key facts: Phase 1 PRX-115 showed rapid, durable urate lowering to 12 weeks at higher doses and generally mild tolerability; an IND for Phase 2 became effective and sites are activated. Commercially, Elfabrio launch metrics track to plan via Chiesi and Elelyso sales continue via Pfizer and Fiocruz. A CHMP negative opinion on a 2 mg/kg E4W Elfabrio regimen is under appeal with an outcome expected in Q1 2026.

2 months ago

#PLX Protalix BioTherapeutics Letter to Stockholders

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

3 months ago

#PLX Secarna’s Antisense Oligonucleotide Discovery Collaboration buff.ly/XcVS2iH

#rarediseases #biotherapeutics #biologics

0 0 0 0

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement Protalix (NYSE American: PLX) and Secarna Pharmaceuticals announced a collaboration and option agreement to discover antisense oligonucleotide (ASO) therapies targeting multiple rare renal indications.Protalix selected biological targets and Secarna will use its OligoCreator® AI platform to design and profile ASO candidates, with the partners aiming to advance programs from preclinical stages toward clinical trials. Secarna grants Protalix an exclusive option for a worldwide, milestone- and royalty-bearing license to develop, market, and commercialize any active compounds from the research.

3 months ago

#PLX Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

www.stocktitan.net/news/PLX/protalix-biothe...

0 0 0 0

ServeTheHome Server Storage and Networking Reviews

@servethehome.com.web.brid.gy

4 months ago

Broadcom Shows the PEX90144 144 lane PCIe Gen6 Switch at SC25 Broadcom showed off its 144-lane PCIe Gen6 (PEX90144) switch at SC25 and showed its roadmap to PCIe Gen7 and Gen8 144-lane switches The post Broadcom Shows the PEX90144 144 lane PCIe Gen6 Switch at SC25 appeared first on ServeTheHome.

0 0 0 0

4 months ago

#PLX: Protalix Seeks Re-Examination of CHMP Opinion buff.ly/EdWJgeU

0 0 0 0

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results CARMIEL, Israel, Nov. 13, 2025/ PRNewswire/-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended September...

4 months ago

#PLX Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for the quarter ended September 30, 2025 and provide a business update on November 13, 2025.Management will host a conference call at 8:00 a.m. Eastern Standard Time with toll-free and international dial-ins and a live webcast. Participants are asked to join 15 minutes early to register and install any required audio software. A replay will be available for two weeks on the company's Investors Events Calendar.

4 months ago

#PLX Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

timontti

@timontti.bsky.social

7 months ago

Välistä vetoa lounaista - lounarifirmat alennuksessa Lainsäätäjien luoma lounassetelimarkkina on suurelta osin kahden ranskalaisen pörssiyhtiön käsissä. Kaksikko kohtaa kilpailua paikallisilta pelureilta, mutta Edenred ja Pluxee ovat ainoita kansainväli...

Molempia löytyy
#plx
#eden

www.sijoitustieto.fi/sijoitusarti...

0 0 0 0

7 months ago

#PLX: New CFO to Take the Reins buff.ly/woUmD9i

0 0 0 0

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results Protalix BioTherapeutics (NYSE American: PLX) reported strong Q2 2025 financial results, with revenues from goods increasing 16% to $15.4 million compared to Q2 2024. The company achieved net income of $164,000 versus a net loss of $2.2 million in the same period last year. The growth was primarily driven by increased sales of Elfabrio® to Chiesi in the $2.3 billion global Fabry disease market.Key developments include the appointment of Gilad Mamlok as new CFO effective August 24, 2025, replacing Eyal Rubin, and the company's addition to the Russell 3000® and Russell 2000® Indexes. Protalix plans to initiate a Phase 2 trial for PRX-115, their gout treatment candidate, in Q4 2025. The company ended the quarter with $33.4 million in cash and cash equivalents.

7 months ago

#PLX Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Protalix BioTherapeutics Earnings: Key Q2 2025 Financial Results and Business Updates Coming August 14 Get exclusive insights into Protalix's Q2 performance, ProCellEx platform developments, and strategic initiatives. Join the live earnings discussion.

7 months ago

#PLX Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Major Milestone: Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes, Gains Access to $10.6T Market Just announced: Protalix joins prestigious Russell indexes, gaining exposure to $10.6T in benchmarked assets. See how this impacts institutional investment potential.

9 months ago

#PLX Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

10 months ago

#PLX: First Quarter Results buff.ly/9MAqhMi

0 0 0 0

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results Protalix BioTherapeutics (NYSE: PLX) reported Q1 2025 financial results, showing significant revenue growth. Revenue from goods increased 170% to $10.0 million compared to $3.7 million in Q1 2024, primarily driven by increased sales to Pfizer ($5.9 million increase). The company reported a net loss of $3.6 million ($0.05 per share), improved from $4.6 million loss in Q1 2024. Research and development expenses increased 21% to $3.5 million, while selling and administrative expenses decreased 16% to $2.6 million. Cash position stood at $34.7 million as of March 31, 2025. The company is advancing its PRX-115 gout treatment candidate, with plans to initiate a Phase II clinical trial in H2 2025 following successful completion of First-in-Human studies.

10 months ago

#PLX Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Protalix Earnings: Biotech Pioneer to Present Q1 2025 Results and Pipeline Updates May 9 Get insights into Protalix's Q1 2025 performance and ProCellEx platform developments. Join the earnings call on May 9 at 8:30 AM EDT. See full details.

10 months ago

#PLX Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

1 year ago

#PLX: 2024 Results buff.ly/RQ42A8U

0 0 0 0

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results Protalix BioTherapeutics (PLX) reported strong financial results for fiscal year 2024, with record revenues from goods sales reaching $53.0 million, a 31% increase from 2023. The growth was primarily driven by an $11.8 million increase in sales to Chiesi.Research and development expenses decreased 24% to $13.0 million, while selling, general and administrative expenses fell 19% to $12.2 million. The company reported net income of $2.9 million ($0.04 per share) compared to $8.3 million in 2023.Key developments include successful completion of First-in-Human phase I trial for PRX-115 (gout treatment candidate), full repayment of outstanding debt, and EMA validation of pegunigalsidase alfa variation submission for less frequent dosing in Fabry disease. The company ended 2024 with $34.8 million in cash and equivalents.

1 year ago

#PLX Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based protein expression system, has scheduled the release of its fiscal year 2024 financial results for March 17, 2025.The company will host a conference call and webcast at 8:30 a.m. EDT on the same day, where management will discuss financial results and provide updates on corporate and regulatory developments. The call will feature a Call me™ functionality for easy access, and a replay will be available for two weeks on the company's website.

1 year ago

#PLX Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

www.stocktitan.net/news/PLX/protalix-bio-th...

0 0 0 0